v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities:    
Net loss $ (1,485,228) $ (1,982,241)
Stock-based compensation expense included in -    
Research and development costs
General and administrative costs 367,737 233,618
Increase (decrease) in -    
Advances on research and development contract services 78,016
Prepaid insurance 6,301 (5,442)
Other prepaid expenses (2,290) (39,824)
Accounts payable and accrued expenses 36,443 (25,354)
Research and development contract liabilities 21,069 132,961
Net cash used in operating activities (1,055,968) (1,608,266)
Cash flows from financing activities:    
Proceeds from sale of securities in registered direct offering, net of offering costs 914,228
Payment of deferred offering costs (10,000)
Net cash provided by financing activities 904,228
Cash:    
Net decrease (151,740) (1,608,266)
Balance at beginning of period 1,038,952 4,203,488
Balance at end of period 887,212 2,595,222
Supplemental disclosures of cash flow information:    
Interest 4,945 11,340
Income taxes
Non-cash investing and financing activities:    
Settlement of accrued compensation to Board of Directors by issuance of stock options 27,500
Conversion of Series A Convertible Preferred Stock into common stock 3,500,000
Accrual of deferred offering costs $ 188,826